Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27501779 | 0.85 | CYP3A4 (0.40) | CYP3A4TDP1L3MBTL1ESR1ESR2 | |
| Bromide SCHEMBL29213552 | 0.80 | CYP3A4 (0.46) | CYP3A4TDP1L3MBTL1ESR1ESR2 | |
| SCHEMBL264229 | 0.79 | — | — | |
| Carbamic Acid SCHEMBL27641323 | 0.74 | CYP3A4 (0.67) | CYP3A4TDP1L3MBTL1ESR1ESR2 | |
| SCHEMBL7445508 | 0.71 | MEN1 (0.42) | CYP3A4L3MBTL1KDM4ESMN1; SMN2HDAC2 | |
| Hydrazinecarboxamide SCHEMBL9305289 | 0.71 | CYP3A4 (0.55) | CYP3A4TDP1L3MBTL1ESR1ESR2 | |
| Succinic Acid SCHEMBL7629002 | 0.71 | CYP3A4 (0.60) | CYP3A4TDP1L3MBTL1ESR1ESR2 | |
| Acetamide SCHEMBL28782962 | 0.71 | CYP3A4 (0.60) | CYP3A4TDP1L3MBTL1ESR1ESR2 | |
| SCHEMBL3353284 | 0.71 | L3MBTL1 (0.72) | CYP3A4L3MBTL1KDM4ESMN1; SMN2KDM1A | |
| SCHEMBL5079803 | 0.70 | CYP3A4 (0.67) | CYP3A4TDP1L3MBTL1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10138190-B2 | Process for preparation of ospemifene | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2018-11-27 | — | — | US | disclosed |
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| WO-2016110805-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| US-7625896-B2 | Pyridylsulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1904471-B1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | disclosed |
| EP-1960361-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1904471-A1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| EP-1888519-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007059872-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F. HOFFMNN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | disclosed |
| WO-2007054139-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208506-B2 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2007006459-A1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | TPMT, BPNT1, SLC6A3 | CYP3A4 264/4885TDP1 1208/4885L3MBTL1 1225/4885 |
| US-10138190-B2 | Process for preparation of ospemifene | CYP3A4, MME, CYP4B1 | CYP3A4 1/4885TDP1 4346/4885L3MBTL1 4044/4885 |
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | CYP3A43, CYP1A1, CYP3A5 | CYP3A4 7/4885TDP1 3682/4885L3MBTL1 999/4885 |
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | CYP3A4, MME, CYP4B1 | CYP3A4 1/4885TDP1 4346/4885L3MBTL1 4044/4885 |
| US-20060270874-A1 | Styrylsulfonamides | STS, SULT1E1, BRCA1 | CYP3A4 222/4885TDP1 2026/4885L3MBTL1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.